Ross, Ashley
Brewer, Kelsie
Hudgens, Stacie
Brown, Bruce
Fallick, Mark
de Paauw-Holt, Simon
Arondekar, Bhakti
Clegg, Jennifer
Hunsche, Elke
Funding for this research was provided by:
Sumitomo Pharma Switzerland GmbH
Pfizer Inc.
Article History
Received: 12 March 2024
Accepted: 25 April 2024
First Online: 11 June 2024
Declarations
:
: Bryan Selby (Senior VP, Product Development, was an employee of Myovant Sciences Inc, Employee, Brisbane, CA); Michael Chladek and Ruby Gogana (were employees of Clinical Outcomes Solutions, COS, Chicago, IL, US; COS was supported by Sumitomo Pharma Switzerland GmbH). Ashley E. Ross is a consultant for Veracyte Inc., Astellas Pharma Inc., Bayer, Blue Earth Inc., Janssen, Lantheus, and Tempus. Kelsie Brewer was an employee of Clinical Outcomes Solutions at the time this study was done. Stacie Hudgens is an employee of Clinical Outcomes Solutions. Bruce Brown was an employee of Myovant Sciences Inc. at the time this study was done. Mark Fallick was an employee of Myovant Sciences Inc. at the time this study was done. Simon dePaauw-Holt is an employee of Sumitomo Pharma Switzerland GmbH. Bhakti Arondekar is an employee of and owns stock in Pfizer, Inc. Jennifer Clegg is an employee of Clinical Outcomes Solutions. Elke Hunsche is an employee of Sumitomo Pharma Switzerland GmbH.
: All research was conducted in compliance with International Conference on Harmonization Guidelines. Study exempt status was granted from the WCG Independent Review Board® (Puyallup, WA) on August 5, 2021. Participants provided written informed consent prior to enrollment.